The APPOSITION IV study will recruit 150 heart attack patients into two treatment groups: patients treated with the STENTYS Self-Apposing Stent and those receiving therapy with Medtronic's Resolute drug-eluting stent. The results - a comparison of stent apposition rates at four or nine months post-treatment - are expected to be announced in 2013.

Stent malapposition has previously been noted as a potential risk of conventional drug-eluting stent usage. Linked to occurrences of stent thrombosis and subsequent adverse clinical events including stent re-clotting, recurrence of heart attack and possible eventual death, the potential to improve apposition rates would be highly desirable to Cardiologists considering therapeutic options for the treatment of acute myocardial infarction.

STENTYS are hopeful that the new Self-Apposing Stent will significantly reduce, or eliminate, the risk of stent malapposition by fitting snugly to the blood vessel contour and then adapting to anatomic changes in the arteries during the post-infarction phase. STENTYS hopes to gain CE mark status for this device in 2014.

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.